The operating income ratio is 0.00 indicating the company's operational profitability margin. The EBITDA is -$79,550,000.00 a key indicator of the company's operational profitability. Furthermore, the net total of other income and expenses is $8,643,000.00 reflecting non-core financial activities. In addition, the weighted average number of shares outstanding is 38,296,428.00 highlighting the company's shareholder base. Notably, the operating expenses amount to $88,193,000.00 encompassing various operational costs incurred as Acrivon Therapeutics, Inc. continues to develop its oncology medicines. Utilizing its proteomics-based patient responder identification platform, the clinical-stage biopharmaceutical company is focused on creating drug-specific proprietary OncoSignature companion diagnostics to effectively identify patients who will benefit from its investigational drug candidates. The lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2 and is currently undergoing a potentially registrational Phase 2 trial across multiple tumor types, such as platinum-resistant ovarian, endometrial, and bladder cancer. The stock is affordable at $1.63 suitable for budget-conscious investors. Additionally, the stock has a low average trading volume of 1,562,377.00 indicating lower market activity. With a market capitalization of $52,697,060.00 the company is classified as a small-cap player. Acrivon Therapeutics is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Strategically, it belongs to the Healthcare sector, driving innovation and growth as it advances its preclinical stage pipeline programs that target critical nodes in the DNA damage response and cell cycle regulation pathways, including WEE1 and PKMYT1.